Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruconest

- PMLiVE

Orphan drugs from Biogen and Amicus win UK Prix Galien

New medical technology category added for the first time

- PMLiVE

Digital Trials

A framework for success

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

- PMLiVE

How pharma should navigate Artificial Intelligence (AI)

Developing an AI strategy that cuts through the hype

- PMLiVE

Lonely planet: why there is dwindling value in pharma travelling alone

To develop sustainable business models that establish value ‘beyond the pill’, collaboration is the best way forward

Pharma social media

Posting frequency is down as companies take a ‘less is more’ approach

Advance Outcomes

Pharma social media

Posting frequency is down as companies take a ‘less is more’ approach

- PMLiVE

Leave or remain? Winning the employee referendum

Six simple things that employers can do to keep their best workers

Insights from the charity sector

Insights from the charity sector – from patient engagement to people-driven design

Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the...

Cuttsy + Cuttsy

- PMLiVE

Wilmington Healthcare adds innovative new features to its digital learning platform for pharma and medtech

Healthcare intelligence provider Wilmington Healthcare has introduced a host of new features to its unique digital learning platform, which enables pharma and medtech sales staff to keep abreast of NHS...

Wilmington Healthcare

The dark side of direct-to-consumer genetic tests

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients...

Blue Latitude Health

- PMLiVE

Alnylam seeks fast-track filing with biomarker data

Early filing reflects FDA desire for faster approvals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links